Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations, Upcoming Webinar Hosted by Xtalks

This webinar will cover the recent advances, challenges and considerations in pediatric drug development, with an emphasis on age-appropriate formulation development. The featured speakers will take attendees through a case study on real-world medications and acceptability assessment.

TORONTO (PRWEB) January 13, 2020 -- In 2018, the US Food and Drug Administration (FDA) released updated guidelines on drug development. That same year, the European Medicines Agency (EMA) also took the initiative to implement additional regulations supporting drug development in Europe. Since the release of these guidelines, overlooking factors such as acceptability, excipient considerations and caregiver instructions are no longer an option.

On Wednesday, January 29, 2020 at 11am EST (4pm GMT/UK), join Matt Ling, Ph. D., Director of Scientific Services, at Catalent and Rachel Meyers, Pharm D., BCPS, BCPPS, FPPA, Clinical Associate Professor at Ernest Mario School of Pharmacy, Rutgers University and Pediatric Clinical Pharmacist, Saint Barnabas Medical Center for a live webinar where they will discuss:

- The impact of age-appropriate dose forms for pediatrics
- Insights into caregiver perspectives
- A case study on real-world medications and acceptability assessment
- Solutions that address the challenges of pediatric drug development
- Factors in excipient decision-making
- Technologies for creating ideal dose forms

This webinar will appeal to individuals working at companies with molecules in late Phase 1 or Phase 2, or in need of advanced dose form for life cycle management purposes.

A live Q&A session with the speakers will follow the presentation. Dr. Matt Ling has over 20 years’ experience in the pharmaceutical industry, much of this gained in big pharma, with roles in analytical, formulation development, advanced drug delivery and project leadership spanning all phases of discovery and development.

Dr. Meyers provides both didactic and experiential education in pediatric pharmacotherapy for pharmacy students and residents in her current position at Rutgers. She practices in the pediatric intensive care unit and the general pediatric unit at Saint Barnabas Medical Center.

For more information or to register for this event, visit Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations.

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product

PRWeb ebooks - Another online visibility tool from PRWeb
performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact Information
Candice Tang
Xtalks
http://www.xtalks.com
1 (416) 977-6555

Online Web 2.0 Version
You can read the online version of this press release [here].